gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

No association between polymorphism of the aromatase (CYP19) and breast cancer risk

Meeting Abstract

  • corresponding author presenting/speaker Peter A. Fasching - Frauenklinik des Universitätsklinikums Erlangen, Deutschland
  • Kerstin Ringleff - Frauenklinik des Universitätsklinikums Erlangen
  • Sonja Geiler - Frauenklinik des Universitätsklinikums Erlangen
  • Stefanie Frank - Frauenklinik des Universitätsklinikums Erlangen
  • Katharina Heusinger - Frauenklinik des Universitätsklinikums Erlangen
  • Sonja Schmidt - Frauenklinik des Universitätsklinikums Erlangen
  • Christian Löhberg - Frauenklinik des Universitätsklinikums Erlangen
  • Ruediger Schulz-Wendtland - Institut fuer diagnostische Radiologie, Universitaetsklinikum Erlangen
  • Pamela Strissel - Frauenklinik des Universitätsklinikums Erlangen
  • Matthias W. Beckmann - Frauenklinik des Universitätsklinikums Erlangen
  • Reiner Strick - Frauenklinik des Universitätsklinikums Erlangen

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO064

The electronic version of this article is the complete one and can be found online at:

Published: March 20, 2006

© 2006 Fasching et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Introduction: Estrogen biosynthesis is catalyzed by aromatase P450 (CYP19). The influence of estrogen on the breast cancer risk has been shown in several large epidemiologic studies. A genetic variation at the gene encoding for CYP19 may be associated with an altered breast cancer risk by affecting the hormone levels of the individual. Aim of this study was to assess the association between breast cancer risk and two single nucleotide polymorphisms (SNP) of the CYP19-gene.

Methods: A case-control study (Erlangen Breast Cancer Association Study) was conducted at the Department of Gynecology and Obstetrics, University Hospital Erlangen. Subjects were 1141 histologically confirmed breast cancer patients and 741 non-hospital controls without cancer. Polymorphisms (SNP a:rs700519 and SNP b: rs10049) were analyzed by RT-PCR with the ABIPrism7000®. Odds ratios (OR) and 95% confidence intervals (95% CI) were determined by logistic regression analysis.

Results: The frequency among controls was 93,5% for theG/G genotype, 6,3% for theA/G genotype and 0,2% for theA/A genotype analysing SNP rs700519. The breast cancer cases showed an equal distribution. Therefore no association for this polymorphism could be found (p=0,984). SNPrs10049 showed a genotype distribution of 29,4% (C/C), 51,0% (C/T) and 19,7% (T/T) for the controls and 30,1% (C/C), 48,6% (C/T) and 21,2% (T/T) for the breast cancer patients. Analysis showed no significant association (p=0,571).

Conclusion: In our study no association between breast cancer risk an polymorphisms of the CYP19-gene could be found. The context of hormonal risk factors seem to be more complex and need further evaluation in a functional setting. Genes interacting with the aromatase function and breast cancer risk have to be taken into consideration for following analysis like estrogen receptor, progesteron receptor, EGFR and HER2.